understanding the context-dependent activity of specific targets, the most important comparison being normal cells vs the disease state. It is challenging to answer these questions precisely in humans; thus, animal models provide a robust system for answering clearly defined questions about context specific function.
LEDGF (also known as PC4 and SFRS1interacting protein 1 or PSIP1) was originally identified as the p75/p52 component of PC4, a transcriptional coactivator. 2 It is also famous for being the integration target of HIV. 3 Importantly, LEDGF also has a crucial role in the development of a rare but aggressive subset of leukemias caused by mutations in the mixed lineage leukemia (MLL) gene. 4 The most common MLL mutations fuse MLL in frame with a wide range of different partner genes creating novel fusion proteins (MLL-FPs). 5 MLL-FPs cause leukemia by binding to gene targets and causing their inappropriate upregulation. LEDGF was originally proposed to be crucial for anchoring MLL-FP proteins to their specific gene targets, 4 but more recent work has suggested that LEDGF may instead have a different role in controlling the assembly of other transcription components at gene targets. 6 Because LEDGF has a clear importance in leukemia progression, several attempts have been made to inhibit the LEDGF/ MLL-FP interaction. 4, [7] [8] [9] One key piece of information that has been missing until now is whether a robust inhibitor would disrupt normal blood development. In other words, is there a therapeutic window where one could effectively target LEDGF without causing more general toxic effects in the blood system? Using a hematopoietic-specific knockout system, El Ashkar et al completely removed LEDGF from normal blood cells in the mouse. They found that, although there were some measurable defects in hematopoiesis, overall the mice were healthy and still retained a fully functional hematopoietic system. Conversely, cells that were deleted for LEDGF were completely resistant to developing MLL-FP-driven leukemia, although other oncogenes were still able to transform these cells. 1 Together, these data suggest that it is now worth developing more robust inhibitors to LEDGF because it appears to be possible to disrupt MLL-FP leukemogenesis without affecting normal blood cell development.
Although this work focuses on a specific target protein that is only important in a rare subset of leukemias, it represents an important proof of principle. This study provides an important example of the robust information needed to justify a more comprehensive drug development program. It also highlights that there may be very few general targets that will work across multiple different cancers. If this is the case, individual patients may themselves represent their own rare kind of cancer, potentially requiring similar specific information on an increasingly wide range of different candidate therapeutic targets. Off-the-shelf TCR for graft-versus-leukemia without GVHD
Frederick L. Locke and Claudio Anasetti | Moffitt Cancer Center and Research Institute
In this issue of Blood, Dossa et al report the engineering of T-cell receptor (TCR) transgenic T cells against the human minor histocompatibility antigen HA-1 for the prevention or treatment of leukemia relapse after allogeneic stem cell transplantation. 1 With the recent US Food and Drug Administration approval of chimeric antigen receptor (CAR) T cells for immunotherapy of CD19 1 B-cell leukemia and lymphoma, 2,3 why pursue such a complex approach for the treatment of hematological malignancies?
The development of adoptive cell therapies for myeloid diseases has not advanced to the same degree as anti-CD19 CAR T-cell therapies. Extensive studies using genomics and proteomics suggest that an ideal surface target may not exist in acute myeloid leukemias (AMLs). 4 Myeloid lineage-specific molecules are shared with hematopoietic stem cells, a clear limitation for the development of CAR T cells directed against nonpolymorphic cell surface receptors: blood® 4 JANUARY 2018 | VOLUME 131, NUMBER 1 5
pancytopenia is not an acceptable toxicity as opposed to B-cell aplasia after anti-CD19 CAR T-cell therapy.
The ability of TCRs to target peptides derived from intracellular proteins in AML and other cancers is a design advantage over CARs. Ideally, the T cell should target mutated proteins that are unique to each individual tumor. Solid tumors induced by carcinogens, for example, melanoma and lung cancer, express numerous mutations that create tumorspecific antigens, which can be targeted by T cells expanded in vivo after neutralizing negative immune checkpoints, 5 or by adoptive transfer of ex vivo expanded tumor-infiltrating lymphocytes. 6 Unfortunately, tumor-specific antigens are rare in hematologic malignancies because of the low mutation load, and alternative immunotherapy targets must be found.
A variety of nonpolymorphic tumorassociated antigens are preferentially expressed on myeloid leukemias, including products of oncogenic mutations, such as the Bcr/Abl tyrosine kinase, tissue-specific proteins, such as proteinase-3, and tumor-selective, overexpressed self-proteins, such as WT1. In general, these are weakly expressed antigens, and it remains uncertain whether they can elicit tumor immunity sufficient for a meaningful clinical impact. 7, 8 Preclinical studies have shown that injection of allogeneic T cells primed against a single minor histocompatibility antigen can cure hematologic and solid cancers without causing toxicity to the host. The key advantage of targeting minor histocompatibility antigens, such as HA-1, for leukemia immunotherapy is their high level of expression that is restricted to hematopoietic tissues, without expression in nonhematopoietic tissues, so that the T cells would neither elicit graft-versushost disease (GVHD) nor cause other undesirable off-target effects. 9
Minor histocompatibility antigens, derived from polymorphic sequences that differ between individuals, are expressed as intracellular proteins, processed, and presented on the leukemia cell surface to TCRs as peptides by HLA molecules. Therefore, the limitations of the proposed approach for cellular immunotherapy of leukemia include the requirement for patient expression of the targeted antigen (HA-1) and the HLA restriction element (HLA-A*02:01) and the need for an allogeneic stem cell transplant from a histocompatible donor that does not express HA-1. The strategy would only work after an allogeneic stem cell transplant from an HA-1-negative donor, because T cells against HA-1 would cause pancytopenia after adoptive transfer into an HA-1-positive recipient. Given these constraints, the approach is translatable to ;15% to 20% of transplanted patients. If successful, it will provide proof of principle applicable to targeting other minor histocompatibility antigens in almost all patients. 10 The authors address several other fundamental problems that could hamper efficacy or safety of the T cells (see table) . These include the weak immunogenicity and variable expression of typical intracellular tumor-associated antigens, which could be targeted by TCR gene therapy; the need for both CD8 1 cytotoxic and CD4 1 helper T cell antitumor specificity; and safety concerns with on-target, off-tumor toxicity to normal myeloid cells. A single lentiviral vector encodes a high affinity TCR against HA-1, a CD8 coreceptor secures the TCR function in CD4 T cells, a selectable marker allows enumeration and enrichment of transfected T cells, and a safety switch could stop the cells in case of toxicity. After transfection, T cells from any donor gain potent antitumor activity.
These elegant molecular biological engineering strategies to target minor histocompatibility antigens combined with allogeneic transplant can overcome specific barriers to successful antitumor immunity for AML. 1 Results of clinical investigation using adoptive transfer of donor T cells engineered with this construct will be eagerly sought. Adoptive cell therapy for AML may now come off the shelf, literally and figuratively. In this issue of Blood, Hill and colleagues characterized infectious complications in patients with relapsed or refractory B-cell malignancies after treatment with CD19-targeted chimeric antigen receptor-modified T (CAR-T) cells in a phase 1/2 study. 1 This is the first study that systemically analyzed infectious events in CAR-T-cell-treated patients.
Adoptive CAR-T-cell immunotherapy has emerged as a promising and novel therapeutic modality for a variety of cancers in recent years. On August 30, 2017, we witnessed the first US Food and Drug Administration approval of a gene therapy product, Kymriah (tisagenlecleucel), an autologous CD19 CAR-T product, and since then, a second CD19-based product, Yescarta (axicabtagene ciloleucel), has been approved. CD19 is universally expressed on most B-cell malignancies. Several groups have developed CD19 CAR-T cells and are at various stages of testing these products for efficacy and safety in patients. Although encouraging remissions are seen with different CD19 CAR-T products, complications such as cytokine release syndrome (CRS) and neurologic toxicities are getting more and more attention. More than 20 years ago, the observation of a sudden release of proinflammatory cytokines during graft-versus-host responses gave CRS its original name, "cytokine storm," and, since then, CRS has been observed as part of many infectious diseases, ranging from streptococcal disease to influenza (reviewed in Tisoncik et al 2012). 2 Thus, CAR therapy appears to engage the same devilish tools occurring in events more commonly seen in sepsis. With more patients receiving CD19 CAR-T treatment, there is increasing observation of infectious diseases associated with CAR-T treatment. Brentjens et al published the first report of sepsis as the potential culprit responsible for a chronic lymphocytic leukemia patient death 40 hours following CD19 CAR-T-cell infusion, although no identifiable pathogen was isolated at autopsy. 3 Nevertheless, Kochenderfer et al recently reported low incidence of severe infection in the 4 diffuse large B-cell lymphoma patients with long-term CR after anti-CD19 CAR-T-cell therapy, despite long periods of B-cell aplasia and hypogammaglobulinemia. 4 Nevertheless, it is reasonable to question the role played by sepsis either in setting the stage for CRS or for worsening its outcome. The authors of this latest study have nicely examined the incidence, onset, types of pathogens, and resolution of infection over time in relationship to CAR-T therapy.
There are several factors predisposing patients to infection while receiving CAR-T therapy. In addition to the pretreatment factors such as impaired immune function and tissue damage from prior chemotherapy regimens, these patients also experience cytopenia caused by the lymphodepletion preceding CAR-T-cell infusion, use of immunosuppressive drugs such as steroids and tocilizumab, possible intensive care unit stay, and subsequent hypogammaglobinemia due to prolonged B-cell aplasia. Intriguingly, this study shows the incidence of infections is comparable to reports from clinical trials using chemo/immunotherapies in similar patient populations. As expected, Hill et al show an increased risk of infections in CAR-treated patients with acute lymphoblastic leukemia, in those having .4 prior lines of antitumor regimens, and in those receiving the highest CAR-T-cell doses. Importantly, the multivariable analysis indicated that only the severity of CRS was a factor associated with infection after CAR-T therapy. Of interest, the incidence of infection was significantly reduced in patients receiving an optimized regimen to reduce the severity of CRS, and it remains unclear how severe CRS leads to infections. A recent study by Hay et al using the same patient population showed severe CRS is characterized by endothelial activation with increased angiopoietin-2 and von Willebrand factor in the blood. 5 It is plausible that CRS-induced endothelial damage might initiate or facilitate infectious processes. Hill et al support this by the observation that in patients with grade 4 or above CRS, the majority (73%) of the infections occurred after the CRS severity grade had peaked. Reducing the severity of CRS should result in less endothelial damage, which in turn might contribute to lower incidence of infection.
With 2 commercial CD19 CAR-T products available and many more in development, the total number of patients receiving CD19 CAR-T cells is expected to increase exponentially in the near future. It is crucial to keep in mind that, although not all fevers are due to CRS, blood® 4 JANUARY 2018 | VOLUME 131, NUMBER 1 7
